Positive Quality Intervention: Vaccination for Non-Transplant Patients with Cancer

Description: Patients undergoing cancer treatment are more susceptible to infections due to their compromised immune system. This PQI will review which vaccinations cancer patients can or cannot use for the proper protection against preventable infections.

Background: Cancer treatments weaken the immune system rendering it more susceptible to infections.\(^1,2\) In order to prevent these infections, cancer patients can either take antimicrobial prophylaxis, get vaccinated, or avoid contact with germs.\(^2\) Generally, it is best to get vaccinated prior to the start of cancer therapy. Live vaccines should be administered at least four weeks prior to the start of chemotherapy and/or at least 3 months after completion of treatment.\(^1,3\) Inactive vaccines should be administered 2 weeks prior to the start of therapy for maximal effect, however, they can be given during therapy. Patients vaccinated during chemotherapy treatment with an inactive vaccine should consider revaccination at least 3 months after therapy as they could be rendered ineffective.\(^3\)

PQI Process:
- Obtain patient vaccination history and reference with CDC recommendations to ensure they are current
- Determine type of vaccination chemotherapy patient needs
  - Non-replicating (inactive) vaccines: should be given at least 2 weeks before the initiation of chemotherapy or other immunosuppressive therapy to maximize immune response\(^1\)
    - Vaccination, 2 weeks prior to chemotherapy, allows for immune response against the targeted pathogen
    - Antibody response is suboptimal if given vaccination during immunosuppressive therapy but is better than not vaccinating; repeat vaccination or boosters may be beneficial in prolonging immunity\(^1,4\)
  - Replicating live vaccines: should be given at least 4 weeks prior to and at least 3 months after immunosuppressive therapy\(^1\)
    - Live vaccinations contain a weak live version of the virus; an immunocompromised system will not be able to fight against the pathogen (may cause vaccine-derived infections)
    - An adequate immune response usually occurs 3 to 12 months after the completion of treatment; wait at least 3 months after the completion of therapy to receive live vaccines\(^5\)
    - Vaccination should be delayed for at least 6 months after treatment if the patient is receiving anti-B-cell antibodies\(^2\)
  - Based on regimen, reference the package insert for all oncolytic specific vaccination suggestions

Patient Centered Activities:
- If patient has not been vaccinated, counsel patient on the importance of vaccination
- Immunocompromised patients are at higher risk for certain diseases; additional vaccines are recommended\(^4\)
  - TIV and polysaccharide-based vaccines (PCV, PPV, MCV4, MPSV, and Hib vaccines)\(^8\)
  - Flu vaccine:

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 11.10.21
• Do NOT get nasal mist flu vaccine since it is a live vaccine
• Influenza-related hospitalization is 3 to 5 times higher in cancer patients

  o Pneumococcal vaccine (PCV13 and PPV23):
    ▪ Immunocompromised patients should receive PCV13 and are recommended to receive PPV23 vaccine about 8 weeks later; then receive a second dose of PPV23 5 years after the first PPV23.
    ▪ Patients that received at least one dose of PPV23 should receive PCV13 no sooner than 1 year after last PPV23 dose.
    ▪ Help patients fight off serious lung, blood, or brain bacterial infections.
    ▪ Recommended in multiple myeloma, lung cancer, chronic lymphocytic leukemia, and lymphoma.

  o Shingrix:
    ▪ Shingrix is an inactivated recombinant vaccine (not recommended due to its lack of research).
  o COVID-19 Vaccine:
    ▪ Moderna – two doses, 4 weeks apart
    ▪ Pfizer-BioNTech – two doses, 3 weeks apart
    ▪ Johnson and Johnson – one dose
    ▪ Booster – Immunocompromised patients receive a booster 4 weeks after initial immunization

• Counsel patients who are on immunotherapy on vaccination recommendations and precautions
  o Immunotherapy has variable immunomodulatory or immunosuppressive effects
  o Vaccine may be triggering an exaggerated immune response in certain patients.
    ▪ Reports suggest that influenza vaccines given to patients on certain types of immunotherapies triggered an amplified immune-related adverse reaction.
    ▪ Some patients receiving immune checkpoint inhibitors experienced intensified immune response.
  o Consult with prescriber if vaccination is appropriate with current immunotherapy

• Follow up with patient 3 months after chemotherapy is complete
  o If patient had inactive vaccine during treatment, remind to revaccinate 3 months post-treatment.
  o If patient is over 65 or has an altered immune system, the CDC recommends a flu vaccine every year.
  o Patients that received at least one dose of PPV23 should receive PCV13 no sooner than 1 year after last PPV23 dose.
  o Booster Tdap vaccination should be considered for patients who have completed chemotherapy.

• Counsel family on risk of receiving live vaccines around patients undergoing chemotherapy

References:
10. https://www.cancernetwork.com/oncology-journal/immunizing-cancer-patients-which-patients-which-vaccines-when-give.

Important notice: NCODA has developed this Positive Quality Intervention platform. This platform represents a brief summary of medication uses and therapy options derived from information provided by the drug manufacturer and other resources. This platform is intended as an educational aid and does not provide individual medical advice and does not substitute for the advice of a qualified healthcare professional. This platform does not cover all existing information related to the possible uses, directions, doses, precautions, warning, interactions, adverse effects, or risks associated with the medication discussed in the platform and is not intended as a substitute for the advice of a qualified healthcare professional. The materials contained in this platform are for informational purposes only and do not constitute or imply endorsement, recommendation, or favoring of this medication by NCODA, which assumes no liability for and does not ensure the accuracy of the information presented. NCODA does not make any representations with respect to the medications whatsoever, and any and all decisions, with respect to such medications, are at the sole risk of the individual consuming the medication. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional. Updated 11.10.21
Supplemental Information: Vaccination Flow Chart:

Table 1: Types of Vaccines

<table>
<thead>
<tr>
<th>Type of Immunization</th>
<th>Principle of Action</th>
<th>Examples</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-replicating vaccines</td>
<td>Based on toxoid, protein subunits, bacterial, antigens, or immunogenic proteins obtained with recombinant, technology.</td>
<td>Tetanus, diphtheria, pertussis, poliomyelitis, hepatitis B, influenza, varicella zoster (shingles) (Shingrix®), Hemophilus influenza, pneumococcus, meningococcus, COVID-19</td>
<td>Usually requires 3–5 doses; antibody titers diminish with time</td>
</tr>
<tr>
<td>Replicating live vaccines</td>
<td>Produced by disabling the virulent properties of a disease-producing virus or bacterium</td>
<td>Measles-mumps-rubella, varicella (chicken pox), intranasal influenza, yellow fever, oral polio, oral typhoid</td>
<td>Severe reactions are possible; transmission of live pathogen may occur; most provide immunity with 1 dose</td>
</tr>
<tr>
<td>Passive immunization</td>
<td>Antibodies are infused to provide short-term protection</td>
<td>Varicella Immunoglobulin, hepatitis B immunoglobulin</td>
<td>Protection diminishes after weeks or months</td>
</tr>
</tbody>
</table>